CREO MEDICAL GROUP PLC Financials Creo Medical Group PLC
Equities
CREO
GB00BZ1BLL44
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35 GBX | -0.71% |
|
-3.45% | -23.91% |
| 04-24 | ActiveOps sales up; Sancus turnover jumps | AN |
| 03-01 | EARNINGS AND TRADING: Dar Global celebrates "outstanding" year | AN |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 239.8 | 272.2 | 306.3 | 265.4 | 45.08 | 122 | 122 | - |
| Enterprise Value (EV) 1 | 195.2 | 191.1 | 273.6 | 232.4 | 43.67 | 98.77 | 125.2 | 108.9 |
| P/E ratio | -12.4 x | -13.9 x | -14.9 x | -9.93 x | -1.68 x | -5.51 x | -10.3 x | -50 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 20,207 x | 32.5 x | 10.5 x | 1.66 x | 3.77 x | 2.98 x | 2.27 x |
| EV / Revenue | - | 14,190 x | 29 x | 9.24 x | 1.61 x | 3.05 x | 3.06 x | 2.03 x |
| EV / EBITDA | -11.4 x | -10.5 x | -12.5 x | -8.5 x | -1.98 x | -5.49 x | -11.8 x | -363 x |
| EV / FCF | - | - | - | -7.3 x | -1.55 x | -5.95 x | -14.6 x | 136 x |
| FCF Yield | - | - | - | -13.7% | -64.5% | -16.8% | -6.87% | 0.73% |
| Price to Book | - | - | - | - | - | 1.97 x | 2.36 x | 2.43 x |
| Nbr of stocks (in thousands) | 120,495 | 150,379 | 157,891 | 178,099 | 178,546 | 348,476 | 348,476 | - |
| Reference price 2 | 1.990 | 1.810 | 1.940 | 1.490 | 0.2525 | 0.3500 | 0.3500 | 0.3500 |
| Announcement Date | 05/04/19 | 07/05/20 | 04/06/21 | 23/05/22 | 26/04/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.0135 | 9.429 | 25.16 | 27.17 | 32.35 | 40.9 | 53.7 |
| EBITDA 1 | -17.17 | -18.23 | -21.89 | -27.34 | -22.08 | -18 | -10.64 | -0.3 |
| EBIT 1 | -17.66 | -18.88 | -23.48 | -29.91 | -30.76 | -21.9 | -14.22 | -4.5 |
| Operating Margin | - | -140,129.03% | -249.07% | -118.86% | -113.2% | -67.7% | -34.77% | -8.38% |
| Earnings before Tax (EBT) 1 | -17.58 | -18.62 | -23.46 | -30.34 | -30.98 | -23.55 | -14.7 | -5.2 |
| Net income 1 | -14.81 | -15.91 | -20.32 | -24.6 | -26.94 | -19.8 | -12.1 | -2.4 |
| Net margin | - | -118,122.87% | -215.46% | -97.75% | -99.14% | -61.21% | -29.58% | -4.47% |
| EPS 2 | -0.1600 | -0.1300 | -0.1300 | -0.1500 | -0.1500 | -0.0635 | -0.0340 | -0.007000 |
| Free Cash Flow 1 | - | - | - | -31.84 | -28.16 | -16.6 | -8.6 | 0.8 |
| FCF margin | - | - | - | -126.54% | -103.66% | -51.31% | -21.03% | 1.49% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 05/04/19 | 07/05/20 | 04/06/21 | 23/05/22 | 26/04/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2023 S1 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | -13.43 | -11.6 |
| Net margin | - | - |
| EPS 2 | -0.0700 | -0.0400 |
| Dividend per Share | - | - |
| Announcement Date | 09/09/22 | 12/09/23 |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 3.23 | - |
| Net Cash position 1 | 44.6 | 81 | 32.7 | 33 | 1.41 | 23.2 | - | 13.1 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.3034 x | - |
| Free Cash Flow 1 | - | - | - | -31.8 | -28.2 | -16.6 | -8.6 | 0.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | -30.1% | -20.5% | -2.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | - | 0.1800 | 0.1500 | 0.1400 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 1.08 | 0.48 | 0.48 | 5.98 | 3.18 | - | - | - |
| Capex / Sales | - | 3,593.24% | 5.14% | 23.75% | 11.7% | - | - | - |
| Announcement Date | 05/04/19 | 07/05/20 | 04/06/21 | 23/05/22 | 26/04/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.35
GBP
Average target price
0.895
GBP
Spread / Average Target
+155.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.91% | 153M | |
| +73.37% | 12.39B | |
| -17.09% | 8.08B | |
| +16.88% | 7.25B | |
| +3.57% | 5.86B | |
| +11.77% | 5.35B | |
| +29.65% | 4.63B | |
| -17.74% | 4.19B | |
| -35.26% | 2.44B | |
| +3.09% | 2.07B |
- Stock Market
- Equities
- CREO Stock
- Financials Creo Medical Group PLC
